Zhou X D, Tang Z Y
Liver Cancer Institute, Zhong Shan Hospital, Shanghai Medical University, People's Republic of China.
Semin Surg Oncol. 1998 Mar;14(2):171-4. doi: 10.1002/(sici)1098-2388(199803)14:2<171::aid-ssu9>3.0.co;2-2.
Between November 1973 and December 1996, the in situ freezing of tumor, i.e., cryotherapy, was performed with liquid nitrogen (-196 degrees C) on 235 patients with primary liver cancer (PLC). There were no operative mortalities or severe complications. The 5-year survival was 39.8% for the 235 PLC patients, and 55.4% for the 80 patients with small PLC (< or = 5 cm). When analyzed with respect to treatment modalities without considering the size of the tumor, the 5-year survival was 26.9% for 78 PLC patients treated by cryotherapy alone; 39.6% for 58 PLC patients treated by cryotherapy plus hepatic artery ligation and perfusion; 46.0% for 27 PLC patients treated by cryotherapy for residual tumor plus resection of the main tumor; and 60.4% for 72 PLC patients treated by cryotherapy followed by resection of the frozen tumor. These results indicate that cryotherapy is a safe and effective treatment for PLC.
1973年11月至1996年12月期间，采用液氮（-196℃）对235例原发性肝癌（PLC）患者进行了肿瘤原位冷冻治疗，即冷冻疗法。无手术死亡病例或严重并发症。235例PLC患者的5年生存率为39.8%，80例小肝癌（≤5cm）患者的5年生存率为55.4%。在不考虑肿瘤大小的情况下，按治疗方式分析，单纯冷冻治疗的78例PLC患者5年生存率为26.9%；冷冻治疗加肝动脉结扎及灌注的58例PLC患者5年生存率为39.6%；冷冻治疗残余肿瘤加切除主肿瘤的27例PLC患者5年生存率为46.0%；冷冻治疗后切除冷冻肿瘤的72例PLC患者5年生存率为60.4%。这些结果表明，冷冻疗法是治疗PLC的一种安全有效的方法。
